COMPUMEDICS APPOINTS EXPERIENCED DIRECTOR FOR NEW MEG DIVISION
- Appointment a major Compumedics’ MEG milestone
- MEG expert, Gordon Haid, appointed as Global Neuro-Imaging Business Director
- Gordon Haid to head international sales push for new MEG Functional-Brain Scanning Division
Compumedics Limited (ASX: CMP) is pleased to announce that it has reached a major milestone with the appointment of Gordon Haid as Global Neuro-Imaging Business Director for Compumedics’ new MEG Functional-Brain Image Scanning Division.
Magnetoencephalography (MEG) is a functional neuroimaging technique for mapping brain activity by recording magnetic fields produced by electrical currents occurring naturally in the brain.
’We are delighted to have Gordon join our team,’ said Dr David Burton, Executive Chairman and CEO at Compumedics. ‘He is an accomplished MEG expert, with an excellent track record including sales of around 30 MEG installations worldwide.’
For nine years Gordon was responsible for Elekta’s key North American MEG market. In more recent times he headed up international MEG sales for York Instruments.
‘Gordon joins Compumedics’ team at an important time in the commercial activation phase of our MEG business,’ said Dr Burton. ’We are experiencing strong demand as our first MEG contract to the world-renowned Barrow Neurological Institute (BNI), based in Phoenix, Arizona nears the delivery and installation phase.
His deep knowledge of the MEG market, coupled with his extensive business development and sales experience will allow Gordon to significantly strengthen this commercial activation phase for Compumedics/Neuroscan’s new-generation Orion MEG system’
About Compumedics Neuroscan Orion LifeSpanTM MEG:
Compumedics has overcome earlier MEG system barriers with the Compumedics Neuroscan Orion LifeSpan™’s increased precision coupled with fully-integrated MEG (Curry MEG) “gold standard” brain analysis software.
At the heart of the new Compumedics Neuroscan Orion LifeSpanTM MEG system is the patented double-relaxation oscillator super conducting quantum interference device (DROS; SQUID) sensor system, which enables 50% greater spatial sampling than the current incumbent market leader.
Additionally, a unique vacuum-cooled dual-helmet design incorporated into a single dewar that enables optimal brain imaging localisation, applicable to the full age-range of adult and paediatric population. Liquid helium supply and costs issues are minimized with cryocooler that provides near 100% coolant recycling (zero loss over 18 months) with continuous 24/7 operation. These advancements contribute to transforming functional brain-health, while providing a sustainable business model reinforced by high barriers of market entry, including patented technological and scientifically proven clinical deployment.
Over a 30-year period Compumedics Neuroscan has established the “gold standard” neurophysiological multi- modality (EEG, MRI, CT, SPECT, PET convergence etc.) and MEG brain analysis platform. In parallel, over a 30-year period the Korean Research Institute of Standards and Science (KRISS) MEG team, led by Dr. Lee have produced the most advanced MEG brain imaging scanner.
MEG provides at least 4-5 orders of magnitude of temporal resolution (speed of brain functional or cognitive measures) over other traditional functional MRI, PET or other conventional imaging systems. The new Orion Lifespan™ MEG presents for functional brain imaging today what MRI was to structural or metabolic imaging in the 80’s and beyond.
For more information on Compumedics Neuroscan Orion LifeSpan™ MEG please visit:
About Compumedics Limited:
Compumedics Limited [ASX: CMP] is a medical device company involved in the development, manufacture and commercialisation of diagnostics technology for the sleep, brain and ultrasonic blood-flow monitoring applications. The Company owns US based Neuroscan and Germany based DWL Elektronishe GmbH. In conjunction with these two subsidiaries, Compumedics has a broad international reach, including the Americas, Australia and Asia Pacific, Europe and the Middle East.
Executive Chairman Dr. David Burton founded Compumedics in 1987. In the same year the company successfully designed and installed the first Australian, fully computerised sleep clinic at Epworth Hospital in Melbourne. Following this early success, Compumedics focused on the development of products that sold into the growing international sleep clinic and home monitoring markets.
Compumedics listed on the Australian Securities Exchange in 2000. Over the years, Compumedics has received numerous awards, including Australia’s Exporter of the Year, and has been recognised as a Top 100 Innovator by both German and Australian governments.
For further information please contact:
Dr. David Burton
Executive Chairman, CEO, Executive Director
Phone: + 61 3 8420 7300
Fax: +61 3 8420 7399
Director and CFO
Phone: + 61 3 8420 7300
Fax: +61 3 8420 7399
Investor Relations, Media & PR enquiries:
Bourse Communications Pty Ltd
Phone: +61 3 9510 8309
Mobile: 0408 670 706
Oxygen Financial PR
Ph: + 61 3 9915 6341
Mob: 0403 493 049